Characteristics of patients in cross-sectional analysis
| . | No GVHD . | Previous episode of GVHD . | GVHD at time of sample . |
|---|---|---|---|
| HSCT recipients 25 years of age | |||
| Total no. | 21 | 17 | 18 |
| Diagnosis* | |||
| Acute leukemia | 6 | 9 | 10 |
| Chronic myelogenous leukemia | 3 | 2 | 1 |
| Lymphoma | 1 | 1 | |
| Aplastic anemia | 2 | 4 | |
| Primary immunodeficiency | 7 | 5 | 3 |
| Genetic hematologic disease | 2 | ||
| Source of HSCs† | |||
| Histocompatible | 12 | 5 | 5 |
| MUD | 7 | 10 | 11 |
| Mismatched family | 2 | 2 | 2 |
| Age at time of HSCT | 1.5-25 years (median = 8) | 0.3-20 years (median = 9.4) | 0.4-16.7 years (median = 8.1) |
| Time after HSCT of TREC analysis | 0.25-5 years (mean = 2.1) | 0.5-7 years (mean = 2.3) | 0.2-12 years (mean = 2.1) |
| Immunosuppression at time of TREC analysis‡ | 3/21 | 7/17 | 16/18 |
| HSCT recipients > 25 years of age | |||
| Total no. | 1 | 6 | 4 |
| Diagnosis* | |||
| Acute leukemia | 2 | ||
| Acute myeloid leukemia | 1 | ||
| Chronic myelogenous leukemia | 1 | 3 | 2 |
| Aplastic anemia | 1 | ||
| MDS | 1 | ||
| Source of HSCs† | |||
| Histocompatible | 1 | 5 | 2 |
| MUD | 1 | 2 | |
| Age at time of HSCT | 37 | 41-58 years (median = 51.5) | 44-53 years (median = 48.5) |
| Time after HSCT of TREC analysis | 2.25 | 0.6-2.6 years (mean = 1.3) | 0.7-7.3 years (mean = 2.4) |
| Immunosuppression at time of TREC analysis‡ | 0/1 | 3/6 | 4/4 |
| . | No GVHD . | Previous episode of GVHD . | GVHD at time of sample . |
|---|---|---|---|
| HSCT recipients 25 years of age | |||
| Total no. | 21 | 17 | 18 |
| Diagnosis* | |||
| Acute leukemia | 6 | 9 | 10 |
| Chronic myelogenous leukemia | 3 | 2 | 1 |
| Lymphoma | 1 | 1 | |
| Aplastic anemia | 2 | 4 | |
| Primary immunodeficiency | 7 | 5 | 3 |
| Genetic hematologic disease | 2 | ||
| Source of HSCs† | |||
| Histocompatible | 12 | 5 | 5 |
| MUD | 7 | 10 | 11 |
| Mismatched family | 2 | 2 | 2 |
| Age at time of HSCT | 1.5-25 years (median = 8) | 0.3-20 years (median = 9.4) | 0.4-16.7 years (median = 8.1) |
| Time after HSCT of TREC analysis | 0.25-5 years (mean = 2.1) | 0.5-7 years (mean = 2.3) | 0.2-12 years (mean = 2.1) |
| Immunosuppression at time of TREC analysis‡ | 3/21 | 7/17 | 16/18 |
| HSCT recipients > 25 years of age | |||
| Total no. | 1 | 6 | 4 |
| Diagnosis* | |||
| Acute leukemia | 2 | ||
| Acute myeloid leukemia | 1 | ||
| Chronic myelogenous leukemia | 1 | 3 | 2 |
| Aplastic anemia | 1 | ||
| MDS | 1 | ||
| Source of HSCs† | |||
| Histocompatible | 1 | 5 | 2 |
| MUD | 1 | 2 | |
| Age at time of HSCT | 37 | 41-58 years (median = 51.5) | 44-53 years (median = 48.5) |
| Time after HSCT of TREC analysis | 2.25 | 0.6-2.6 years (mean = 1.3) | 0.7-7.3 years (mean = 2.4) |
| Immunosuppression at time of TREC analysis‡ | 0/1 | 3/6 | 4/4 |
GVHD indicates graft-versus-host disease; HSC, hematopoietic stem cell; MUD, matched unrelated donor; HSCT, hematopoietic stem cell transplantation; TREC, T-cell receptor excision circle; and MDS, myelodysplastic syndrome.
Acute leukemias were acute lymphoblastic (22) and nonlymphoblastic (3) leukemia. Primary immunodeficiencies were severe combined immunodeficiency (8), Wiskott-Aldrich syndrome (3), CD40 ligand deficiency (1), and hemophagocytic lymphohistiocytosis (3). Genetic hematologic diseases were sickle cell disease (1) and chronic granulomatous disease (1).
Matched unrelated donors were 6/6 HLA matched (18) or 1 locus mismatched (11). Mismatched family donors were haploidentical and T-cell depleted (5), or 1 HLA locus mismatch without T-cell depletion (1).
Immunosuppression at time of TREC analysis included prednisone (29), cyclosporine or tacrolimus (36), and mycophenolate (11).